Quest PharmaTech Inc.
Quest PharmaTech Inc. (Quest) is a Canada based company which is involved in discovering, developing and commercializing pharmaceutical products. The company by using its Sonolight technology platform is developing a series of drugs for the treatment of cancer and dermatological conditions. The product pipeline of the company includes SL017, is a topical formulation indicated for hair removal applications and also for Actinic Keratosis and acne vulgaris. Quest offers SL052, an injectable formulation for prostate cancer treatment. In addition the other cancer therapies such as chemotherapy, photodynamic therapy or radioimmuno therapy, for the treatment. The company is headquartered in Edmonton, Canada.The company reported revenues of (Canadian Dollars) CAD 2.01 million during the fiscal year ended January 2009, an increase of 249.22% over 2008. The operating loss of the company was CAD 0.42 million during the fiscal year 2009, as compared to an operating loss of CAD 1.33 million during 2008. The net loss of the company was CAD 0.20 million during the fiscal year 2009, as compared to a net loss of CAD 1.32 million during 2008.